Anti-CTLA-4 therapy for malignant mesothelioma

References

• 1 Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet 366(9483), 397–408 (2005).
  Medline CASGoogle Scholar
• 2 Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 13(4), 255–263 (2006).
  MedlineGoogle Scholar
• 3 Robinson BW, Lake RA. Advances in malignant mesothelioma. N. Engl. J. Med. 353(15), 1591–1603 (2005).
  Medline CASGoogle Scholar
• 4 Neumann V, Loseke S, Nowak D, Herth FJ, Tannapfel A. Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. Dtsch. Arztebl. Int. 110(18), 319–326 (2013).
  MedlineGoogle Scholar
• 5 Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin. Oncol. 29(1), 2–17 (2002).
  Medline CASGoogle Scholar
• 6 Testa JR, Cheung M, Pei J et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43(10), 1022–1025 (2011).
  Medline CASGoogle Scholar
• 7 Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34(7), 1413–1419 (2013).
  Medline CASGoogle Scholar
• 8 Napolitano A, Antoine DJ, Pellegrini L et al. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin. Cancer Res. 22(12), 3087–3096 (2016).
  Medline CASGoogle Scholar
• 9 Hollevoet K, Sharon E. Fibulin-3 as a biomarker for pleural mesothelioma. N. Engl. J. Med. 368(2), 189–189 (2013).
  MedlineGoogle Scholar
• 10 Cristaudo A, Foddis R, Bonotti A et al. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int. J. Biol. Markers 25(3), 164–170 (2010).
  Medline CASGoogle Scholar
• 11 Cristaudo A, Foddis R, Vivaldi A et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin. Cancer Res. 13(17), 5076–5081 (2007).
  Medline CASGoogle Scholar
• 12 Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21(14), 2636–2644 (2003).
  Medline CASGoogle Scholar
• 13 Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 588(2), 368–376 (2014).
  Medline CASGoogle Scholar
• 14 Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J. Clin. Invest. 125(9), 3335–3337 (2015).
  MedlineGoogle Scholar
• 15 Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J. Clin. 62(5), 309–335 (2012).
  MedlineGoogle Scholar
• 16 Neves H, Kwok HF. Recent advances in the field of anti-cancer immunotherapy. BBA Clinical 3, 280–288 (2015).
  MedlineGoogle Scholar
• 17 Hanoteau A, Moser M. Chemotherapy and immunotherapy: a close interplay to fight cancer? Oncoimmunology 5(7), e1190061 (2016).
  MedlineGoogle Scholar
• 18 Blank CU, Enk A. Therapeutic use of anti-CTLA-4 antibodies. Int. Immunol. 27(1), 3–10 (2015).
  Medline CASGoogle Scholar
• 19 Ascierto PA, Marincola FM, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J. Transl. Med. 9 (2011).
  Google Scholar
• 20 Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
  Medline CASGoogle Scholar
• 21 Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int. J. Clin. Oncol. 21(3), 462–473 (2016).
  Medline CASGoogle Scholar
• 22 Mccoy KD, Le Gros G. The role of CTLA-4 in the regulation of T-cell immune responses. Immunol. Cell Biol. 77(1), 1–10 (1999).
  Medline CASGoogle Scholar
• 23 Bakker E, Qattan M, Mutti L, Demonacos C, Krstic-Demonacos M. The role of microenvironment and immunity in drug response in leukemia. Biochim. Biophys. Acta 1863(3), 414–426 (2016).
  Medline CASGoogle Scholar
• 24 Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B-cell activation antigen B7 to CD28 costimulates T-cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173(3), 721–730 (1991).
  Medline CASGoogle Scholar
• 25 Jago CB, Yates J, Camara NO, Lechler RI, Lombardi G. Differential expression of CTLA-4 among T-cell subsets. Clin. Exp. Immunol. 136(3), 463–471 (2004).
  Medline CASGoogle Scholar
• 26 Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol. Rev. 229(1), 126–144 (2009).
  Medline CASGoogle Scholar
• 27 Zou W, Chen L. Inhibitory B7-family molecules in the tumor microenvironment. Nat. Rev. Immunol. 8(6), 467–477 (2008).
  Medline CASGoogle Scholar
• 28 Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270(5238), 985–988 (1995).
  Medline CASGoogle Scholar
• 29 Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5), 541–547 (1995).
  Medline CASGoogle Scholar
• 30 Wu L, Yun Z, Tagawa T, Rey-Mcintyre K, De Perrot M. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol. Cancer Ther. 11(8), 1809–1819 (2012).
  Medline CASGoogle Scholar
• 31 Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy 5(3), 215–229 (2013).
  CASGoogle Scholar
• 32 Currie AJ, Prosser A, Mcdonnell A et al. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J. Immunol. 183(12), 7898–7908 (2009).
  Medline CASGoogle Scholar
• 33 Mansfield AS, Roden AC, Peikert T et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J. Thorac. Oncol. 9(7), 1036–1040 (2014).
  Medline CASGoogle Scholar
• 34 Combaz-Lair C, Galateau-Salle F, Mcleer-Florin A et al. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum. Pathol. 52, 9–18 (2016).
  Medline CASGoogle Scholar
• 35 Khanna S, Thomas A, Abate-Daga D et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J. Thorac. Oncol. 11(11), 1993–2005 (2016).
  MedlineGoogle Scholar
• 36 Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin. Chem. 59(1), 85–93 (2013).
  Medline CASGoogle Scholar
• 37 Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 23(Suppl. 8), viii6–9 (2012).
  MedlineGoogle Scholar
• 38 Guo Y, Wang AY. Novel immune check-point regulators in tolerance maintenance. Front. Immunol. 6, 421 (2015).
  MedlineGoogle Scholar
• 39 Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin. Cancer Res. 17(14), 4622–4628 (2011).
  Medline CASGoogle Scholar
• 40 Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint blockade in cancer therapy. J. Clin. Oncol. 33(17), 1974–U1161 (2015).
  Medline CASGoogle Scholar
• 41 Choe N, Tanaka S, Xia WJ, Hemenway DR, Roggli VL, Kagan E. Pleural macrophage recruitment and activation in asbestos-induced pleural injury. Environ. Health Perspect. 105, 1257–1260 (1997).
  Medline CASGoogle Scholar
• 42 Anraku M, Cunningham KS, Yun Z et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 135(4), 823–829 (2008).
  MedlineGoogle Scholar
• 43 Hegmans JPJJ, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur. Respir. J. 27(6), 1086–1095 (2006).
  Medline CASGoogle Scholar
• 44 Mutti L, Valle MT, Balbi B et al. Primary human mesothelioma cells express class II MHC, ICAM-1 and B7–2 and can present recall antigens to autologous blood lymphocytes. Int. J. Cancer 78(6), 740–749 (1998).
  Medline CASGoogle Scholar
• 45 Sigalotti L, Coral S, Altomonte M et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br. J. Cancer 86(6), 979–982 (2002).
  Medline CASGoogle Scholar
• 46 Castagneto B, Zai S, Mutti L et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion – results of a Phase II study on 31 consecutive patients. Lung Cancer 31(2–3), 303–310 (2001).
  Medline CASGoogle Scholar
• 47 Valle MT, Porta C, Megiovanni AM et al. Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone. Int. J. Mol. Med. 11(2), 161–167 (2003).
  Medline CASGoogle Scholar
• 48 Powell A, Creaney J, Broornfield S, Van Bruggen I, Robinson B. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer 52(2), 189–197 (2006).
  MedlineGoogle Scholar
• 49 Calabro L, Sigalotti L, Fonsatti E et al. Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications. J. Cell. Physiol. 226(10), 2595–2600 (2011).
  Medline CASGoogle Scholar
• 50 Calabro L, Morra A, Fonsatti E et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, Phase 2 trial. Lancet Oncol. 14(11), 1104–1111 (2013).
  Medline CASGoogle Scholar
• 51 Nishino M GM, Suda M, Ramaiya Nh, Hodi FS. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J. Immunother. Cancer 2(17), (2014).
  Google Scholar
• 52 Wolchok JD, Hoos A, O'day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412–7420 (2009).
  Medline CASGoogle Scholar
• 53 Nishino M. Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a ‘common language’ for the new arena of cancer treatment. J. Immunother. Cancer 4(30), (2016).
  Google Scholar
• 54 Weber JS, Hamid O, Chasalow SD et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J. Immunother. 35(1), 89–97 (2012).
  Medline CASGoogle Scholar
• 55 Vonderheide RH, Lorusso PM, Khalil M et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T Cells. Clin. Cancer Res. 16(13), 3485–3494 (2010).
  Medline CASGoogle Scholar
• 56 Calabro L, Morra A, Fonsatti E et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, Phase 2 study. Lancet Respir. Med. 3(4), 301–309 (2015).
  Medline CASGoogle Scholar
• 57 AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma. www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html.
  Google Scholar
• 58 Kindler HL, Scherpereel A, Calabrò L et al. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): results from the global, double-blind, placebo-controlled DETERMINE study. Presented at: 2016 ASCO Annual Meeting. Chicago, IL, USA, 3–7th June (2016).
  Google Scholar
• 59 Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39(1), 98–106 (2016).
  Medline CASGoogle Scholar
• 60 Alley EW, Molife LR, Santoro A et al. Abstract CT103: clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028. Cancer Res. 75(15 Suppl.), CT103–CT103 (2015).
  Google Scholar
• 61 Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122–133 (2013).
  Medline CASGoogle Scholar
• 62 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23–34 (2015).
  Medline CASGoogle Scholar
• 63 Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin. Transl. Sci. 9(2), 89–104 (2016).
  Medline CASGoogle Scholar
• 64 Calabrò L, Morra A, Giannarelli D et al. Tremelimumab and durvalumab (MEDI4736) combination for first and second-line treatment of mesothelioma patients: the NIBIT-MESO-1 study. Presented at: 2016 ASCO Annual Meeting. Chicago, IL, USA, 3–7th June (2016).
  Google Scholar
• 65 Feig C, Jones JO, Kraman M et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110(50), 20212–20217 (2013).
  Medline CASGoogle Scholar